A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients by Fahad J. Alharbi et al.
B The Author(s), 2016. This article is published with open access at Springerlink.com
DOI: 10.1007/s13361-015-1318-4
J. Am. Soc. Mass Spectrom. (2016) 27:719Y725
RESEARCH ARTICLE
ANovel RapidMALDI-TOF-MS-BasedMethod for Measuring
Urinary Globotriaosylceramide in Fabry Patients
Fahad J. Alharbi,1 Tarekegn Geberhiwot,2 Derralynn A. Hughes,3 Douglas G. Ward1
1Institute of Cancer and Genomic Sciences, College ofMedical and Dental Sciences, University of Birmingham, Birmingham, B15
2TT, England
2Queen Elizabeth Medical Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, England
3Department of Haematology, Lysosomal Storage Disorders Unit, Royal Free Hospital, London, NW3 2QG, England
Abstract. Fabry disease is an X-linked lysosomal storage disorder caused by defi-
ciency of α-galactosidase A, resulting in the accumulation of glycosphingolipids in
various organs. Globotriaosylceramide (Gb3) and its isoforms and analogues have
been identified and quantified as biomarkers of disease severity and treatment
efficacy. The current study aimed to establish rapid methods for urinary Gb3 extrac-
tion and quantitation. Urine samples from 15 Fabry patients and 21 healthy control
subjects were processed to extract Gb3 by mixing equal volumes of urine, methanol
containing an internal standard, and chloroform followed by sonication and centrifu-
gation. Thereafter, the lower phasewas analyzed byMALDI-TOFMS and the relative
peak areas of the internal standard and four major species of Gb3 determined. The
results showed high reproducibility with intra- and inter-assay coefficients variation of 9.9% and 13.7%, respec-
tively. The limit of detectionwas 0.15 ng/μL and the limit of quantitationwas 0.30 ng/μL. Total urinaryGb3 levels in
both genders of classic Fabry patientswere significantly higher than in healthy controls (p < 0.0001). Gb3 levels in
Fabry males were higher than in Fabry females (p = 0.08). We have established a novel assay for urinary total
Gb3 that takes less than 15 min from start to finish.
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Introduction
Fabry disease (FD) is a rare multi-systemic X-linked lyso-somal storage disorder . This inborn error of
glycosphingolipid metabolism results from the absence or de-
ficiency of alpha-galactosidase A (α-GAL A, OMIM 301500),
which is responsible for hydrolytic cleavage between the ga-
lactose residues in globotriaosylceramide (Gb3). The un-
metabolized glycosphingolipids accumulate in various organs,
resulting in a range of pathologies in the kidneys, heart, brain,
eye, peripheral nervous system, and skin. Male patients show
symptoms at an early age whereas females display symptoms
when older. The precise incidence of FD is not known: the
reported figures vary widely. The rarity of the disease and wide
spectrum of symptoms displayed by Fabry patients make diag-
nosis based on clinical manifestation problematic. FD is cur-
rently diagnosed by measuring the activity of α-GAL A and/or
by mutation analysis of the α-GAL A gene where enzyme
analysis may not be informative in females [1–7].
Enzyme replacement therapy (ERT), using recombinant α-
GAL A has become the standard treatment for symptomatic
Fabry patients since 2001 [8–10]. However, the clinical benefit
of this expensive treatment is limited, depending on the clinical
stage at which therapy is initiated. Gb3 levels in plasma or
urine can be used to monitor the efficacy of ERT and as a
diagnostic biomarker although with limited sensitivity [11–17].
Gb3 levels in biological samples decrease considerably within
2 wk of starting ERT but later increase in some patients
probably due to development of α-GAL A antibodies and do
not show a good correlation with effects on clinical symptoms
or organ function [11, 12].
Gb3 and its isoforms/analogues have been detected at ele-
vated levels in plasma and urine of Fabry patients using mass
spectrometric approaches [14, 15, 18–21]. Several analytical
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methods have been reported for urinary Gb3 extraction and
analysis. Auray-Blais and co-workers originally used filter
paper discs saturated with urine, which were dried and Gb3
extracted with methanol and analyzed by LC-MS/MS [14].
Later, Krüger and colleagues [15] combined liquid extraction/
protein precipitation and solid phase extraction for urinary Gb3
extraction before LC-MS/MS analysis. Despite being fairly
complex and time-consuming, these methods generated invalu-
able data on urinary Gb3 levels in FD. Recently, an advanced
multiplex method has been established by Auray-Blais team
where they were successful in measuring the levels of different
Gb3 isoforms and analogues using liquid–liquid extraction and
LC-MS/MS [19, 20].
In this study, we report the development of a rapid, robust
assay for Gb3 based on a novel liquid–liquid extraction
followed by MALDI-TOF MS, and validate it using




Fabry patients with diagnoses confirmed by mutation analysis
and enzyme activity test were enrolled in the study after giving
written informed consent (ethical approval reference: 09/
H1010/75). Urine samples were collected from 15 classic
Fabry patients and 21 age- and gender-matched healthy con-
trols (patient details are shown in Supplemental Information
Table S1). Urine samples were stored at –80 °C until further
processing without any centrifugation or filtration. Classic
Fabry patients are defined as having typical Fabry disease
manifestations and known classic mutations with the deficien-
cy of α-GAL A enzyme activity (<1%).
Chemicals
HPLC grade water and acetonitrile (ACN) were purchased
from (VWR International-UK). Acetone was purchased from
(Fisher Scientific, Loughborough, UK). HPLC grade methanol
(MeOH, ≥99.9%), HPLC grade chloroform (CHCl3, ≥99.9%),
5-chloro-2-mercaptobenzothiazole (5C2M), 2-mercap-
tobenzothiazole, 6-aza-2-thiothymine, 2-(4-hydroxyphenylazo)
benzoic acid, 2,5-dihydroxy benzoic acid (DHB), super-DHB,
sinapic acid, 2,4,6-trihydroxy acetophenone monohydrate, 2,5-
dihydroxy acetophenone, α-cyano-4-hydroxycinnamic acid,
picolinic acid, and 9-aminoacridine hemihydrate were purchased
from (Sigma Aldrich, Gillingham, UK). Porcine Gb3 standard
and N-heptadecanoyl ceramide trihexoside (C17:0) internal stan-
dard were purchased from Matreya (Pleasant Gap, PA, USA).
Total Gb3 Standard
Total Gb3 (source: porcine RBC) was used for method devel-
opment and standard curve purposes. Total Gb3 stock solution
(200 ng/μL) was prepared by dissolving 10mg of Gb3 standard
in 50 mL of MeOH, then stored at –20 °C.
Gb3 Internal Standard
N-heptadecanoyl ceramide trihexoside internal standard
(0.5 mg) was dissolved in 1 mL of MeOH:CHCl3 (2:1) and
then 9 mL of MeOH was added to generate 10 mL of internal
standard at 50 ng/μL. This solution was stored at –20 °C in
glass until used as 2 ng/μL.
Extraction of Urinary Gb3
One hundred μL each of urine, MeOH containing 200 ng of
Gb3 internal standard, and CHCl3 were mixed and incubated in
a sonicating water bath for 5 min at room temperature. The
mixture was then centrifuged at 13,000 rpm for 5 min and 1 μL
of the lower (CHCl3) layer spotted directly onto a stainless steel
384-position MALDI target in triplicate.
MALDI-TOF-MS
Once dry, the samples were overlaid with 1 μL of 5C2Mmatrix
(saturated solution in 50%MeOH). MS and MS/MS (using
laser induced dissociation in LIFT mode) were acquired on a
Bruker Ultraflextreme TOF instrument equipped with a 1 kHz
laser in positive ion mode. The MS spectra used for quantita-
tion were the sum of 20,000 laser shots acquired in a random
walk pattern. The peak areas used for Gb3 quantitation were
extracted from the spectra using ClinproTools software
(Bruker).
Gb3 Internal Standard and Assay Calibration
N-heptadecanoyl ceramide trihexoside was used as the internal
standard throughout this study. A standard curve was produced
by extracting a series of Gb3 dilutions ranging from (0 to 40)
ng/μL made in depleted urine from a healthy individual con-
taining 2 ng/μL internal standard. The depleted urine was
prepared by passing through a C18 cartridge and effective
removal of Gb3 confirmed by parallel depletion of urine from
a classic Fabry patient analyzed byMALDI-MS (Supplemental
Information, Figure S-1). The four most abundant Gb3 species
have been used to calculate the urinary total Gb3 level. The
sodiated molecular ions of Gb3 species are at mass-to-charge
ratios (m/z) of: 1130.7 (C22:0), 1146.7 (C22:0-OH), 1158.7
(C24:0), and 1174.7(C24:0-OH). The main peak of the Gb3
internal standard is at m/z 1060.7 (C17:0) with a secondary
peak at m/z 1076.7 (C17:0-OH). The total area of both internal
standard peaks and all four Gb3 species were used to determine
the response ratio (Equation 1) and used in conjunction with a
calibration curve to determine urinary Gb3 concentrations.
Response ratio ¼ total area of the 4 most abundant Gb3 species
area of Gb3 internal standard
ð1Þ
The limit of detection (LOD) and the limit of quantitation of
total Gb3 in urine were determined using (Equation 2) and
(Equation 3) respectively, where F = 3.3 and 10 for LOD and
720 F. J. Alharbi et al.: MALDI-TOF-MS Method for Urinary Gb3 Analysis
LOQ respectively, stdev = standard deviation and b: slope of
the regression line (Supplemental Information Figure S-2).
LOD ¼ F  stdev
b
ð2Þ




Optimization of Gb3 Extraction from Urine
Depleted urine was spiked with 2.5 μL of porcine total Gb3
standard [200 ng/μL] generating a final concentration of 5 ng/
μL, and the performance of various extraction procedures
involving different volumes of MeOH, acetone, and CHCl3
were assessed by MALDI-TOF-MS. We found using 1:1:1
(v:v:v) of urine, MeOH, and CHCl3 to be the optimal condition
for Gb3 extraction into the hydrophobic layer (CHCl3 layer)
based on peak intensity and signal-to-noise ratio in the mass
spectra (Figure 1) with no Gb3 detectable in the aqueous layer
(Supplemental Information Figure S-3).
Optimization of MALDI-TOF-MS
We acquired and compared the MALDI spectra for depleted
urine spiked with 5 ng/μL Gb3 using 12 different matrix
compounds (spectra shown in Supplemental Information
Figure S-4). The matrices were used as saturated solutions both
in 50%MeOH and 50% ACN. Spectra obtained with 5C2M in
50% MeOH provided the best signal intensity and signal-to-
noise ratio. Example MS spectra showing Gb3 peaks in the
urine of a Fabry patient, porcine Gb3 standard, and a healthy
control subject are shown in (Figure 2).
MS/MS Confirmation of Gb3 Peaks in Fabry
Patient Urine
MS spectra of Fabry patient urine contain peaks with exactly
the same m/z values as those in purchased porcine Gb3:m/z
1046.7 (predicted structure C16:0), 1074.7(C18:0),
1102.7(C20:0), 1128.7(C22:1), 1130.7(C22:0), 1146(C22:0-
OH), 1156.7(C24:1), 1158.7(C24:0), 1172.7(C24:1-OH:),
and 1174.7(C24:0-OH). To confirm that the peaks in Fabry
patient urine spectra correspond to Gb3, they were subjected to
MALDI-TOF/TOF MS/MS. The MS/MS spectra of the urine
peaks show the loss of sugar moieties (Figure 3) and confirm
Figure 1. Validation of liquid-liquid extraction using different solvents: (a) acetone: MeOH:H2O, (45:45:10) (b) MeOH:CHCl3, (2:1) (c)
MeOH:CHCl3 (1:1)
F. J. Alharbi et al.: MALDI-TOF-MS Method for Urinary Gb3 Analysis 721
that these ions correspond to Gb3 species by the presence of the
fragment m/z 264.2, which represents sphingosine (sphingo-
sine-2[H2O]). The purchased porcine Gb3 generated identical
MS/MS spectra (data not shown).
Quantitative Measurement of Urinary Gb3
by MALDI-TOF-MS
To correct for variations in extraction and ionization efficien-
cies an internal standard was added to all urine samples prior to
extraction. The internal standard appears as a peak at m/z
1060.7 (C17:0) (plus a secondary peak at m/z 1076.7(C17:0-
OH)). No peaks were seen at these m/z values in the MALDI
spectra of any of the extracted urines used in this study in the
absence of internal standard (Supplemental Information
Figure S-5) (also, no contaminants with the same masses as
the Gb3 peaks were detected). Gb3 concentrations were calcu-
lated from the (total Gb3/internal standard) area ratio as de-
scribed in Methods and using the calibration curve shown in
Figure 4. Inter-assay and intra-assay variability were measured
to assess the reliability of the method. Urine samples of 10
healthy controls were used. Each sample was spiked with
2.5 μL of total Gb3 standard [200 ng/μL] generating a final
concentration of 5 ng/μL. Each sample was processed as three
independent technical replicates. Each extract was spotted onto
the MALDI target in triplicate giving nine readings for each
sample. The same procedure was repeated on three different
days resulting in each sample being analyzed 27 times. The
results showed high reproducibility and reliability of the meth-
od with an intra-assay coefficient of variation of 9.9% and
inter-assay of 13.7%. The lower limit of detection was
0.15 ng/μL, and limit of quantitation was 0.30 ng/μL. The
assay was linear up to the highest Gb3 concentration investi-
gated (40 ng/μL).
Urinary Gb3 Levels in Fabry Patients
Wemeasured the levels of urinary Gb3 in classical Fabry patients
(n = 15) and healthy controls (n = 21) as shown in Figure 5. The
mean Gb3 concentrations in classic patients and healthy controls
were 1.35 ng/μL and 0.08 ng/μL, respectively. Prior to statistical
comparison, the urinary Gb3 concentrations were normalized to
urinary creatinine. Overall, the mean normalized concentration in
the classic Fabry patients was significantly higher than healthy
controls (n = 21, mean = 6.7 μg=mmolcreat), (p < 0.0001). The
normalized mean concentration in the classic Fabry males was
higher than in Fabry females (171.7 v 57.9 μg=mmolcreatinineÞ
although thisdidnot reachstatistical significance (p = 0.08), and
Figure 2. MS spectra of Gb3 species and Gb3 internal standard in (a) purchased porcine Gb3 standard, (b) urine from an untreated
classic Fabry male, and (c) healthy control urine
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urinary Gb3 was significantly higher in both male and female FD
patients than in healthy controls (p < 0.0001 in both cases). Using
the urinary Gb3 concentrations measured in the 36 individuals in
this study to detect Fabry disease generated a receiver operator
characteristic (ROC) curve with an area of 0.92 (95% CI 0.79–
1.00) and, using a threshold of 25 μg/mmol creatinine gave a
sensitivity of 80% (95% CI 52–96) at 100% specificity (95% CI
84–100), (Supplemental Information Figure S-6).
Gb3 generates multiple peaks inmass spectra. The total area of
the four most intense peaks [m/z 1130.7 (C22:0), 1146.7 (C22:0-
OH), 1158.7 (C24:0), and 1174.7(C24:0-OH)] was used to mea-
sure the ratio of Gb3 to the internal standard. These four peaks
were selected because they have the highest intensities, and they
were detected in all patients whereas the other peaks (other Gb3
species) were not always detected.We found that the ratio of these
four peaks to one another is constant across individuals (i.e.
Figure 3. MALDI-TOF/TOF MS/MS of (a) Gb3-Internal standardm/z 1060.7 (C17:0); and the three most abundant Gb3 species in
Fabry patient urine:m/z 1130.7 (C22:0), 1158.7 (C24:0), and 1174.7 (C24:0-OH). The peaks corresponding to ions generated by the
loss of 1 or 2 sugars (–162 and –324 Da, respectively) have different m/z values for each species, whereas the fragments
corresponding to sphingosine –2H20, (m/z 264.1) and di- and tri-saccharide ions (m/z 347 and 509) are invariant
y = 0.7229x 
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Figure 4. Gb3 standard curve. Increasing amounts of porcine
Gb3 standard covering the reported clinical range and a con-
stant amount of Gb3 internal standard were spiked into deplet-
ed urine from a healthy control subject. Thereafter, the lipids
were extracted and analysed by MALDI-TOF MS
Figure 5. Urinary total Gb3 levels: box-and-whiskers plot
showing urinary Gb3 levels in both genders of classical Fabry
patients and healthy control subjects (P values obtained using
t-tests)
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classic FD results in accumulation of all 4 Gb3 species). Although
we have used the sum of the four main peaks for quantitation
(considering that this might be the most robust approach), we also
found that any one of the four peaks alone would yield the same
results (data not shown).
Discussion
By coupling a novel liquid–liquid extraction and MALDI-TOF-
MS with an internal standard, we have been able to develop a
rapid (<15 min from start to finish) method for measuring Gb3 in
urine. Considerable optimization of the Gb3 extraction and MS
analysis has been performed to produce an assay with good
reproducibility, sensitivity, and specificity sufficient to easily de-
tect the elevated levels of urinary Gb3 that are expected in classic
Fabry patients. N-heptadecanoyl ceramide trihexoside has been
used as an internal standard in this study because it has very
similar chemical properties to human Gb3 but cannot be synthe-
sized by humans (due to the odd number of carbon atoms). The
internal standard generates a main peak atm/z 1060.7 (C17:0) and
a minor peak at m/z 1076.7 (C17:0-OH) (most likely due to
oxidation, both peaks were combined in calculations). Following
liquid–liquid extraction human urine is devoid of peaks at these
m/z values unless the internal standard is added (Supplemental
Information Figure S-5). Including the internal standard in our
assay has enabled a high degree of reducibility and reliability to be
reached with correspondingly low intra-assay and inter-assay
coefficients of variation. The assay is based on MS; however,
MS/MSwas used to verify the identity of the Gb3 peaks: the most
abundant peaks at m/z 1130.7 (C22:0), 1146.7 (C22:0-OH),
1158.7 (C24:0), and 1174.7 (C24:0-OH) all show identical frag-
mentation pattern by losing sugar groups (–162 Da) and generat-
ing the di-dehydrated sphingosine moiety (m/z 264.2) as previ-
ously reported for Gb3 [13, 14, 16, 18, 22].
Conclusion
Our method significantly reduces the number of steps and time
required to complete the test compared with the current stan-
dard methods. The method could be easily implemented in any
laboratory with access to a MALDI mass spectrometer and
used for noninvasive, cost-effective detection of Fabry disease.
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